Roberto Salgado

37.8k total citations · 8 hit papers
147 papers, 8.7k citations indexed

About

Roberto Salgado is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Roberto Salgado has authored 147 papers receiving a total of 8.7k indexed citations (citations by other indexed papers that have themselves been cited), including 113 papers in Oncology, 66 papers in Cancer Research and 37 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Roberto Salgado's work include Cancer Immunotherapy and Biomarkers (74 papers), Breast Cancer Treatment Studies (36 papers) and Cancer Genomics and Diagnostics (33 papers). Roberto Salgado is often cited by papers focused on Cancer Immunotherapy and Biomarkers (74 papers), Breast Cancer Treatment Studies (36 papers) and Cancer Genomics and Diagnostics (33 papers). Roberto Salgado collaborates with scholars based in Belgium, Australia and United States. Roberto Salgado's co-authors include Sherene Loi, Christos Sotiriou, Peter Savas, Stefan Michiels, Carsten Denkert, Martine Piccart, Mark J. Smyth, Nicolas Sirtaine, Evandro de Azambuja and Stephen J. Luen and has published in prestigious journals such as Journal of Clinical Investigation, Nature Medicine and Nature Communications.

In The Last Decade

Roberto Salgado

141 papers receiving 8.6k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98

2013 1.2k citations Sherene Loi, Nicolas Sirtaine et al. Journal of Clinical Oncology profile →
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

2014 956 citations Sherene Loi, Stefan Michiels et al. Annals of Oncology profile →
Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis

2017 662 citations Roberto Salgado, Peter Savas et al. profile →
Clinical relevance of host immunity in breast cancer: from TILs to the clinic

2015 638 citations Peter Savas, Roberto Salgado et al. profile →
The 2019 World Health Organization classification of tumours of the breast

2020 547 citations Stephen B. Fox, Roberto Salgado et al. Histopathology profile →
Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab

2015 432 citations Roberto Salgado, Peter Savas et al. profile →
Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study

2020 279 citations Roberto Salgado, Sherene Loi et al. Annals of Oncology profile →
Towards targeting the breast cancer immune microenvironment

2024 119 citations Peter Savas, Balaji Virassamy et al. profile →

Peers

Countries citing papers authored by Roberto Salgado

Since Specialization

Citations

This map shows the geographic impact of Roberto Salgado's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roberto Salgado with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roberto Salgado more than expected).

Fields of papers citing papers by Roberto Salgado

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roberto Salgado. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roberto Salgado. The network helps show where Roberto Salgado may publish in the future.

Co-authorship network of co-authors of Roberto Salgado

This figure shows the co-authorship network connecting the top 25 collaborators of Roberto Salgado. A scholar is included among the top collaborators of Roberto Salgado based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roberto Salgado. Roberto Salgado is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Quantitative proteomics analysis of triple-negative breast cancers 2025 ·npj Precision Oncology ·(unknown), Jonathan D. Marotti, Youdinghuan Chen, (unknown), Roberto Salgado, Brock C. Christensen, Todd W. Miller, Arminja N. Kettenbach	1
2	Practical implementation of AI in a non‐academic, non‐commercial Pathology laboratory: Real world experience and lessons learned 2025 ·Histopathology ·Frederik Deman, Glenn Broeckx, Sabine Declercq, (unknown), (unknown), Roberto Salgado, Amélie Dendooven	1
3	Preliminary characterisation of the spatial immune and vascular environment in triple negative basal breast carcinomas using multiplex fluorescent immunohistochemistry 2025 ·PLoS ONE ·Elena A. Takano, (unknown), (unknown), (unknown), Roberto Salgado, Sherene Loi, Stephen B. Fox	1
4	Reproducible Reporting of the Collection and Evaluation of Annotations for Artificial Intelligence Models 2024 ·Modern Pathology ·(unknown), (unknown), Víctor García, Amy Ly, Evangelos Hytopoulos, (unknown), Matthew G. Hanna, Dieter Peeters, Joel Saltz, Anna Ehinger, Sarah Dudgeon, Xiaoxian Li, Kim Blenman, Weijie Chen, Ursula Green, (unknown), Tony Pan, Jochen K. Lennerz, Roberto Salgado, Brandon D. Gallas	6
5	1943P Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: A joint SITC and INMC effort 2024 ·Annals of Oncology ·(unknown), Elizabeth M. Burton, Ashley Cimino‐Mathews, Tricia R. Cottrell, Carlos E. de Andrea, (unknown), Jeffrey E. Gershenwald, (unknown), Jane L. Messina, Roberto Salgado, Christian M. Schürch, Raja R. Seethala, Lynette M. Sholl, Sabina Signoretti, M.T. Tetzlaff, B. van de Wiel, Xiaowei Xu, Richard A. Scolyer, Janis M. Taube	0
6	NeoTRACT: Phase II trial of neoadjuvant tumor infiltrating lymphocyte- and response-adapted chemoimmunotherapy for triple-negative breast cancer (TNBC). 2024 ·Journal of Clinical Oncology ·Shane R. Stecklein, (unknown), Roberto Salgado, Anne O’Dea, Lauren Nye, Kelsey E. Larson, (unknown), Ryan K. Rader, Rashna Madan, Rachel Yoder, Joshua M. Staley, (unknown), (unknown), Jamie L. Wagner, Christa Balanoff, (unknown), Leonidas E. Bantis, Andrew K. Godwin, Qamar J. Khan, Priyanka Sharma	3
7	Automated mitotic spindle hotspot counts are highly associated with clinical outcomes in systemically untreated early-stage triple-negative breast cancer 2024 ·npj Breast Cancer ·Roberto A. Leon‐Ferre, Jodi M. Carter, David M. Zahrieh, Jason P. Sinnwell, Roberto Salgado, Vera J. Suman, David W. Hillman, Judy C. Boughey, Krishna R. Kalari, Fergus J. Couch, James N. Ingle, Maschenka Balkenhol, Francesco Ciompi, Jeroen van der Laak, Matthew P. Goetz	1
8	Abstract PO2-07-05: Deep learning model for automated quantification of HER2 expression in invasive breast cancers from immunohistochemical whole slide images 2024 ·Cancer Research ·(unknown), (unknown), (unknown), (unknown), Charles Maussion, (unknown), Anca Mera, (unknown), Cheryl Gillett, Elinor J. Sawyer, Patrycja Gazińska, Piotr Ziółkowski, Roberto Salgado, Sheeba Irshad	1
9	Association between tumor-infiltrating lymphocytes and survival in patients with metastatic breast cancer receiving first-line chemotherapy: analysis of CALGB 40502 2024 ·npj Breast Cancer ·Daniel G. Stover, Roberto Salgado, (unknown), Karla V. Ballman, Erica L. Mayer, Mark Jesus M. Magbanua, Sherene Loi, (unknown), (unknown), Mark A. Watson, Yujia Wen, W. Fraser Symmans, Charles M. Perou, Lisa A. Carey, Ann H. Partridge, Hope S. Rugo	4
10	Sustained lymphocyte decreases after treatment for early breast cancer 2024 ·npj Breast Cancer ·(unknown), Balaji Virassamy, (unknown), (unknown), Stephen J. Luen, Peter Savas, (unknown), Steven David, Prudence A. Francis, Roberto Salgado, Stefan Michiels, Sherene Loi	2
11	Characterization of the Tumor Microenvironment of De Novo Oligometastatic Breast Cancer in a Nationwide Cohort 2023 ·JCO Precision Oncology ·Tessa G. Steenbruggen, Denise M. Wolf, Bram Thijssen, Joyce Sanders, Sten Cornelissen, Roberto Salgado, Lorenza Mittempergher, Rajith Bhaskaran, Annegien Broeks, Esther H. Lips, Sabine Siesling, Gabe S. Sonke, Hugo M. Horlings, Laura van ‘t Veer	1
12	Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727) 2023 ·Clinical Cancer Research ·Holly Tovey, (unknown), Joel S. Parker, Katherine A. Hoadley, Jelmar Quist, Sarah Kernaghan, Lucy Kilburn, Roberto Salgado, Sherene Loi, Richard D. Kennedy, Ioannis Roxanis, Patrycja Gazińska, Sarah E. Pinder, Judith M. Bliss, Charles M. Perou, Syed Haider, Anita Grigoriadis, Andrew Tutt, Maggie C.U. Cheang	3
13	Computational pathology in cancer diagnosis, prognosis, and prediction – present day and prospects 2023 ·The Journal of Pathology ·(unknown), Jochen K. Lennerz, Danny Ruta, (unknown), Selvam Thavaraj, Kalliopi P. Siziopikou, Threnesan Naidoo, Swapnil Rane, Roberto Salgado, Sarah E. Pinder, Anita Grigoriadis	34
14	Leveraging the Dynamic Immune Environment Triad in Patients with Breast Cancer: Tumour, Lymph Node, and Peripheral Blood 2022 ·Cancers ·(unknown), (unknown), (unknown), Kim Blenman, Yin Wu, (unknown), Dinis Pedro Calado, Roberto Salgado, Anita Grigoriadis	7
15	Comparative Evaluation of Tumor-Infiltrating Lymphocytes in Companion Animals: Immuno-Oncology as a Relevant Translational Model for Cancer Therapy 2022 ·Cancers ·(unknown), Andrew Lagree, Fang‐I Lu, Jonathan Klein, Michelle L. Oblak, Roberto Salgado, (unknown), Barbara Brunetti, Luisa Vera Muscatello, Giuseppe Sarli, Maria Pia Foschini, Alexandros Hardas, (unknown), Khalid AbdulJabbar, Yinyin Yuan, David A. Moore, William T. Tran	13
16	Seeing the forest and the tree: TILs and PD-L1 as immune biomarkers 2021 ·Breast Cancer Research and Treatment ·Peter Savas, Roberto Salgado, Sherene Loi	12
17	Systemic immune reaction in axillary lymph nodes adds to tumor-infiltrating lymphocytes in triple-negative breast cancer prognostication 2021 ·npj Breast Cancer ·Fangfang Liu, (unknown), Kailiang Wu, Jelmar Quist, Patrycja Gazińska, Tony Ng, Arnie Purushotham, Roberto Salgado, Xiaojing Guo, Sarah E. Pinder, Anita Grigoriadis	12
18	Characterization of Stromal Tumor-infiltrating Lymphocytes and Genomic Alterations in Metastatic Lobular Breast Cancer 2020 ·Clinical Cancer Research ·François Richard, Samira Majjaj, David Venet, Françoise Rothé, (unknown), Bram Boeckx, Caterina Marchiò, Florian Clatot, François Bertucci, Odette Mariani, Christine Galant, Gert Van den Eynden, Roberto Salgado, Elia Biganzoli, Diether Lambrechts, Anne Vincent‐Salomon, Giancarlo Pruneri, Denis Larsimont, Christos Sotiriou, Christine Desmedt	19
19	Multidisciplinary quality assurance and control in oncological trials: Perspectives from European Organisation for Research and Treatment of Cancer (EORTC) 2017 ·European Journal of Cancer ·Christine de Balincourt, Denis Lacombe, Corneel Coens, Marcel den Dulk, Jean‐Pascal Machiels, Damien C. Weber, Martin Spahn, Roberto Salgado, Bernd Kasper, Peter Hau, Lisa Licitra, Fay Betsou, Kozo Kataoka, Carmela Caballero, Yan Liu, Coen Hurkmans, Serge Évrard	13
20	Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98 breakdown → 2013 ·Journal of Clinical Oncology ·Sherene Loi, Nicolas Sirtaine, Fanny Piette, Roberto Salgado, Giuseppe Viale, (unknown), Ghizlane Rouas, Prudence A. Francis, John Crown, Erika Hitre, Evandro de Azambuja, Emmanuel Quinaux, Angelo Di Leo, Stefan Michiels, Martine Piccart, Christos Sotiriou	1213

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact